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Summary Topoisomerase inhibitors constitute a new class of anti-cancer agents. Recently, topotecan and irinotecan were registered for
clinical use in ovarian cancer and colorectal cancer respectively. Cytotoxicity oftopoisomerase inhibitors is S-phase specific, and in vitro and
in vivo studies have suggested that, forefficacy, prolonged exposure might be more importantthan short-term exposure to high concentration.
Clinical development of those topoisomerase inhibitors that have reached this stage is also focused on schedules aiming to achieve
prolonged exposure. In this review, we summarize all published preclinical studies on this topic for topoisomerase inhibitors in clinical
development, namely 20-S-camptothecin, 9-nitro-camptothecin, 9-amino-camptothecin, topotecan, irinotecan and G1147211. In addition,
preliminary data on clinical studies concerning this topic are also reviewed. The data suggest that prolonged exposure may indeed be
relevant for anti-tumour activity. However, the optimal schedule is yet to be determined. Finally, clinical data are yet too immature to draw
definitive conclusions.
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Topoisomerase 1-3' is a nuclear enzyme abundantly present in all
eukaryotic cells (Roca, 1995). Human topoisomerase 1-3' is a
monomeric 100-kDa polypeptide encoded by a single-copy gene
located on chromosome 20ql2-13.2 (Juan et al, 1988). Like all
topoisomerases, topoisomerase I relaxes torsionally strained
(supercoiled) duplex DNA. A tyrosine group of topoisomerase I
becomes covalently bound to the 3'-phosphate at the DNA break
site (cleavable complex). To accomplish DNA relaxation, topo-
isomerase I introduces a single-strand nick in the phosphodiester
backbone ofthe DNA, allows the intact strand to pass through the
nick and then rejoins the nicked strand. DNA relaxation results
from swiveling at this nick and plays an important role in DNA
replication and RNA transcription. The enzyme-bridged breaks
are then resealed by topoisomerase I (religation) (Champoux,
1976; D'Arpa et al, 1989; Roca, 1995).
Topoisomerase enzymes provide an essential function in
solving topological problems encountered in DNA replication
and DNA transcription. Topoisomerase may also be involved in
recombinational processes and chromatin assembly, however their
roles in these processes are less well defined (D'Arpa et al, 1989).
As long ago as the 1970s, camptothecin (CPT), an extract from
the chinese tree Camptotheca acuminata, was showed to have anti-
tumour activity against several tumours. However, in phase I and
II studies, unpredictable severe toxicities occurred that led to the
discontinuation offurther development (Wall et al, 1966; Gottlieb
et al, 1970; Creaven et al, 1972; Moertel et al, 1972; Muggia et al,
1972). In the late 1980s, studies revealed that camptothecin
Received29 November 1996
Revised26 March 1997
Accepted 1 April 1997
Correspondence to: CJH Gerrits, Department Medical Oncology, Rotterdam
Cancer Institute (Daniel den Hoed Kliniek), and University Hospital, Groene
Hilledijk 301, 3075 EA Rotterdam, The Netherlands
induced single-strand DNA breaks in the presence of topoiso-
merase I, thus identifying this enzyme as a major target for the
antitumour effect (Hsiang et al, 1988). The cellulareffects ofcamp-
tothecin can be entirely attributed to its action on topoisomerase I
as has been proven in genetic studies with yeast and mammalian
cells (Andoh et al, 1987; Gupta et al, 1988; Kjeldsen et al, 1988;
Nitiss et al, 1988; Eng et al, 1989). Topoisomerase I cleavable
complexes occur preferentially within expressed genes (Stewart et
al, 1987; D'Arpa et al, 1989).
The lactone form ofcamptothecin (CPT) and all CPT analogues
appears to reversibly stabilize the cleavable complex, which
results in single-strand DNA breaks and inhibition ofreligation in
the presence ofthe drug. DNA synthesis is arrested in the presence
oftopoisomerase I inhibitors - religation does not occur, resulting
in irreversible inhibition of DNA synthesis with double-strand
DNA breaks. These events lead to the arrest ofthe cell cycle in the
S-G2 phase and ultimately cell death (Hsiang et al, 1989). A S-
phase specific cytotoxicity for topoisomerase I inhibitors has been
observed, as S-phase cells are up to 1000-fold more sensitive than
G1 or G2/M-phase cells after brief exposure to the drug (Liu et al,
1972; Drewinko et al, 1974; D'Arpa et al, 1980). Analysis of the
distribution of RNA polymerase molecules indicates that CPT-
stabilized cleavable complexes block elongation by impeding the
progression ofthe RNA polymerase molecules along the transcrip-
tion unit (Zhang et al, 1988). Inhibition of RNA synthesis is
rapidly reversible after removal ofCPT from cultured cells, prob-
ably as a result of the dissociation of topoisomerase I cleavable
complexes from transcription units. Thus, camptothecin demon-
strates inhibition of DNA and RNA synthesis with fragmentation
of nuclear DNA but, upon removal of the drug, nucleic acid
synthesis inhibition and DNA fragmentation are reversible and,
only at higher dose and longer exposure times, do these effects
become irreversible (Horwitz et al, 1971-1973; Kessel, 1971;
Horwitz, 1974). Cytotoxicity of topoisomerase I drugs in the
absence ofdetectable DNA synthesis has also been found in some
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cell lines, such as human lymphocytes. The mechanism of this
non-S-phase cytotoxicity is unknown but could be due to tran-
scription inhibition (Bruno et al, 1992). Other effects of camp-
tothecin analogues are induction of maturation in a variety of
leukaemia cell lines, expression of proto-oncogenes and endo-
nucleolytic DNA damage characteristic of apoptosis (Kaufmann,
1989; Chou et al, 1990; Del Bino et al, 1991; Kharbanda et al,
1991; Ling et al, 1991; McSheehy et al, 1991; Aller et al, 1992).
Topoisomerase I inhibitors are active both in slowly and rapidly
proliferating tumours (Liu et al, 1981; Hwang et al, 1989).
Sensitivity of tumour cells to these drugs is related to the topo-
isomerase I level, topoisomerase I catalytic activity and the
interaction between topoisomerase I and its inhibitor, hence the
importance of intracellular drug concentration.
Topoisomerase I is present at relatively high levels in both
proliferating and quiescent cells, suggesting that its function may
be independent ofcellular growth rate. In proliferating cells, topo-
isomerase I mRNA levels are significantly higher than in quiescent
cells. However topoisomerase I protein is increased much less,
which may be due to a shorter half-life of the protein in prolifer-
ating cells than in resting cells (Hwang et al, 1989, 1993). The
catalytic activity of topoisomerase I also depends on the phos-
phorylation state of the enzyme, and phosphorylation has been
shown to increase during mitogenic stimulation of quiescent
cells (Samuels et al, 1992).
The regulation of topoisomerase I is altered in neoplastic cells.
Colon cancer cells, for example, contain a five- to sixteen-fold
higher level of topoisomerase I than normal colon mucosa cells
(Giovanella et al, 1989; Sabiers et al, 1993).
Despite high levels oftopoisomerase I, some human tumour cell
lines are nevertheless resistant to topoisomerase I inhibitors, which
may be attributed to a low specific activity ofthis form oftopoiso-
merase I (Sugimoto et al, 1990; Tanizawa et al, 1990; Takeda et al,
1992). The effect oftopoisomerase I inhibitors on the enzyme can
also be influenced by point mutations ordeletions within the topoi-
somerase I genes that affect protein or enzyme activity levels
(Saijo et al, 1994). An absolute low level of topoisomerase I is
another mechanism of resistance to topoisomerase I inhibitors
(Andoh et al, 1987; Gupta et al, 1988; Kanzawa et al, 1990;
Sugimoto et al, 1990).
In order to exert inhibitory effects, topoisomerase I inhibitors
have first to enter tumour cells, while anti-tumour activity is only
achieved with the lactone form of the compounds. This lactone
form has a relatively short half-life and, at physiological pH, the
hydroxyl moiety will predominate. Topoisomerase I inhibitors
show readily reversible interaction with the target enzyme and do
not form an intracellular reservoir (Covey et al, 1989; Subramanian
et al, 1995). Therefore exposure ofonly limited duration oftumour
cells to the active lactone form oftopoisomerase I inhibitors will be
achieved in dose schedules with short-lasting infusions. Related to
cell entry, Ma et al (1996) reported an ovarian cancer cell line that
is resistant to topotecan and SN38 because ofa decreased influx of
the drug (Ma et al, 1996). In a CPT- 1I multidrug-resistant cell line,
the cellular concentration of the drug appeared dependent on the
plasma transmembrane potential (Aogi et al, 1994).
P-glycoprotein overexpression does not influence the intra-
cellular drug concentration of camptothecin, and many of its non-
charged derivatives, MDR-1-overexpressing cells, are more
resistant to the positively charged camptothecin-derivative
topotecan (Chen et al, 1991; Hendricks et al, 1992; Liu et al, 1992).
In vitro studies with topoisomerase I inhibitors suggest that
cytotoxicity increases upon prolonged exposure to the drug.
This review will further summarize the preclinical and clinical
studies of continuous or long-term exposure of topoisomerase I
inhibitors in cancer research.
20-S-CAMPTOTHECIN
20-S-camptothecin (20-S-CPT) has been identified as the active
agent in the extract of the Camptotheca tree (Wall et al, 1966).
20-S-CPT is water insoluble.
Stereochemistry and the positions of substituents have been
found to be crucial in CPT and its analogues for the presence or
absence of effects on topoisomerase I, indicating that the
compounds interact with an asymmetrical receptor site on the
enzyme or enzyme-DNA complex (Jaxel et al, 1989). The R-
camptothecin isomer has little or no effect on topoisomerase I, in
contrast to the natural S-isomer which has a single asymmetrical
carbon located at position 20.
Interaction with the receptor is influenced by configurational
alterations causing little change in general chemical properties of
topoisomerase I inhibitors but producing marked changes in topo-
isomerase I interaction (Jaxel et al, 1989).
The lactone form of the topoisomerase I inhibitor, which
predominates at pH < 4.0, is the more potent inhibitor of the
enzyme and therefore a much more potent anti-tumour agent than
the inactive open-ring compound.
Preclinical studies
In vivo studies
Antineoplastic and toxic effects in L1210 leukaemia of intra-
peritoneal administration ofthe 20-S-CPT sodium (20-S-CPT-Na+)
formulation were found to vary with the schedule of administra-
tion (Venditti, 1971). An intermittent schedule (days 1,5 and 9)
of administration appeared superior on the resulting lifespan
compared with any of the alternative treatment schedules studied,
being a day 1-9 single daily dosing; dosing every 3 h on day 1, 5
and 9; every 3 h on day 1 or dosing with a single dose on day 1
(Guarino et al, 1973; Schaeppi et al, 1974).
The sodium salt of 20-S-CPT is not the optimal formulation of
administration. Prolonged administration ofwater-insoluble formu-
lations of 20-S-CPT were recently studied in nude mice bearing
human cancer xenografts. To test the efficacy of the lipophilic
moiety 20-S-CPT was dispersed in intralipid 20% and injected
intramuscularly (i.m.) at a dose of0.1 mg per 25 g ofbody weight.
The same formulation was also administered orally and intra-
venously. Intravenous 20-S-CPI resulted in toxic deaths without
inhibitory effects. Tested against 13 human cancerxenografts resis-
tant to the most commonly available chemotherapeutic agents,
20-S-CPIT given i.m. at a dose of 4 mg kg-' twice weekly induced
complete regression in the majority of the animals in 10 out of 13
xenografts. Only one melanoma and two colon cancers showed a
poor response. Daily oral administration of 20-S-CPT at a dose of
4-8 mg kg-' resulted in complete tumour regression in mice
carrying SPA lung carcinoma. After 6 months of continuous treat-
ment, regrowth was observed in five of the seven xenografts,
suggesting 20-S-CPT resistance under prolonged treatment
(Giovanella et al, 1991). 20-S-CPT given i.m. at a dose of
4 mg kg-' twice daily also induced complete regression in BRO
British JournalofCancer (1997) 76(7), 952-962 0 CancerResearch Campaign 1997954 CJH Gerrits etal
melanoma xenografts. In vitro cell proliferation ofthe same cell line
was inhibited at a remarkably low concentration of 1 ng ml-', and it
was demonstrated that a period of 20-24 h of drug exposure was
required for complete growth inhibition (Pantazis et al, 1992). In
this model, 20-S-CPT i.m. (2 mg kg-') appeared to be the most
effective mode of drug administration to induce tumour inhibition
compared with i.v ori.p administration. 20-S-CPT at a dose of2 mg
kg-' day-1 x 2 intragastrically followed by one day ofrest was more
effective in inducing complete tumour inhibition than 1 mg kg-'
day-' x 5 (intragastrically) with two days rest (Pantazis et al, 1994).
Nude mice bearing intracranial human brain tumour xenografts
were treated with intraperitoneal (i.p.) 20-S-CPT in different
schedules. Single doses of CPT did not prolong survival, but CPT
i.p. twice per week for 6 weeks or daily oral 20-S-CPT induced 10
weeks' survival in 40% or 60% ofanimals respectively (Phillips et
al, 1994). In addition, 20-S-CPT administered intragastrically at
an intermittent weekday schedule for 10 weeks was well tolerated
and induced tumour responses in human cancer xenografts of
malignant melanoma and colon carcinoma (Potmesil et al, 1995).
In order to bypass the insolubility of 20-S-CPT lactone, the
compound can also be incorporated into a liposome-based delivery
system for i.m. administration. Release studies of liposomal 20-S-
CPT show an initial rapid 50% loss of the drug in 4 h, followed by
a slow leakage of the remaining drug over a period of 20 h.
Complete tumour regression occurred after a single i.m. injection
of this formulation at 10 mg kg-1 in nude mice xenografted with
CLO breast carcinoma or BRO melanoma, with minimal host toxi-
city (Daoud et al, 1995).
Lipid-complexed 20-S-CPT bypasses its insolubility and makes
prolonged low-dose exposure possible.
These preclinical studies suggest that intermittent intraperi-
toneal or more convenient daily oral administration of 20-S-CPIT
for a prolonged period is well tolerated and may have anti-tumour
effects. Anti-tumour effects seem to be dose and schedule depen-
dent. The intramuscular or oral administration of camptothecin
seems to enable protracted dose scheduling.
Clinical studies with camptothecin and prolonged
exposure
Daily x 5 i.v. administration
In the early 70s, three phase I studies with intravenous administra-
tion of the sodium 20-S-camptothecin (20-S-CPT-Na+) were
performed in which 20-S-CPT-Na+ (0.5-10 mg kg-') was adminis-
tered as single i.v. bolus every 2-4 weeks. Myelosuppression with
leucopenia and thrombocytopenia was the dose-limiting toxic
effect. Diarrhoea, reversible haemorrhagic cystitis and alopecia
were observed at higher dose levels (Gottlieb et al, 1970). Muggia
et al (1972) studied i.v. 20-S-CPT-Na+ at a once weekly and daily
x 5 schedule every 3 weeks. On the weekly schedule, dose-
limiting toxicities (DLTs) were leuco- and thrombocytopenia,
while haemorrhagic cystitis occurred in several patients who
received multiple doses. Cumulative leuco- and thrombocytopenia
were also dose limiting with the daily x 5 schedule, resulting in
haemorrhagic cystitis in 3 of 17 patients (Muggia et al, 1972).
Phase II trials with 20-S-CPT-Na+ have been performed in
patients with melanoma and advanced gastrointestinal carcinomas.
Melanoma patients were treated with 20-S-CPT-Na+ every
2 weeks (Gottlieb et al, 1972). Patients with gastrointestinal
carcinoma were treated with either single-dose 20-S-CPT-Na+
(90-180mg m-2 every 3 weeks or a daily x 5 schedule (11-55
mg m-2 day-') every 4 weeks (Moertel et al, 1972). Both treatment
schedules showed equal toxicity. Because of severe and unpre-
dictable myelosuppression, haemorrhagic cystitis and diarrhoea,
the sodium salt formulation ofcamptothecin was then disregarded.
Prolonged exposure
However, results of the above mentioned preclinical studies
recently renewed the interest in new formulations of camp-
tothecin, and the drug is again undergoing phase I evaluation. 20-
S-CPT in gelatin capsules administered orally once a day for 21
days followed by 1 week rest was studied in 52 patients. Doses
were escalated from 0.3 to 15.4 mg m-2 day-' (Stehlin et al, 1995).
DLT of 20-S-CPT over a 3-week period was diarrhoea. Loose
stools occasionally occurred in all patients at doses above 6.5 mg
m-2 day-' with a 32% incidence of persistent diarrhoea. Anti-diar-
rhoeal medication generally solved this problem. The maximum
tolerated dose was 8.7 mg m-2 day-'.Chemical cystitis, resulting in
dysuria and occasional haematuria occurred in 20% of patients. It
resolved within a week of drug discontinuation but sometimes
reappeared with continued administration. Only two extensively
pretreated patients experienced severe haematological toxicity,
recovering within 10-14 days. In 12 patients, the oral administra-
tion of 20-S-CPT could be continued for 6-12 months, in five
patients for more than 1 year. No long-term toxicities were
reported. Partial responses occurred in two patients with breast
cancer and two patients with melanoma, and one patient with non-
Hodgkin lymphoma achieved a complete remission.
Thus, it is possible to administer orally 20-S-CPT to patients
with solid tumours for a long period of time without inducing
long-term cumulative haematological or non-haematological toxi-
city. Presently, 20-S-camptothecin has entered a phase II study.
9-NITRO-CAMPTOTHECIN, 9-AMINO-
CAMPTOTHECIN
9-Nitro-camptothecin (9NC) is a semisynthetic derivative of the
natural product camptothecin and is water insoluble. 9NC is a
precursor required for the synthesis of 9-amino-camptothecin
(9AC) from CPT. 9NC is chemically more stable than 9AC,
which is oxidized readily, generating toxic degradation products
(Hinz et al, 1994; Pantazis et al, 1994). An additional finding
is that 9NC is converted to 9AC by human cells of solid tissue
of origin. Conversion of 9NC is less in haematopoietic cells.
Cellular conversion of the lactone form of 9NC to 9AC is
maximal in a slightly acidic environment (pH 6.0) (Hinz et al,
1994; Pantazis et al, 1994a). Because of this relationship, results
of preclinical and clinical studies of both compounds will be
discussed under one heading.
Preclinical studies
In vivo studies
In vivo studies of9NC and 9AC in the malignant melanoma BRO
xenograft showed that, after40 days oftreatment with i.m. 9NC or
9AC at 4 mg kg-' twice a week, all engrafted mice were tumour
free and did not experience significant toxicity. Growth inhibition
of BRO cells in vitro occurred at a low 9NC concentration of
1 ng ml and was complete after a period of 20-24 h of exposure
(Pantazis et al, 1992).
Nude mice inoculated with three tumorigenic breast cancer cell
lines developed complete tumour regression when treated with
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Table 1 Topoisomerase inhibitors - continuous/prolonged administration in solid tumours (9-amino-camptothecin)
Drug Dose Number of patients Cp-ss MTD DLT Reference
schedule
9-Amino-CPT i.v 5-59 ,ug m-2 h-1 35 ,ug m-2 h-1 Neutropenia
72hq 14d
48 0.9-10.6 nm Dahut et al (1996)
47-74 jg m-2 47 jg m-2 h-1 Neutropenia
72 h q 14 d Thrombopenia
+ G-CSF
9-Amino-CPT i.v. - 19 - - Neutropenia Rubin et al (1994)
72 h
9-Amino-CPT i.v. 36-62 jg m-2h-1 18 2.23 ng ml-' Not yet reached Myelosuppression Langevin et al (1996)
72 h q 14 d
9-Amino-CPT i.v. 6.2-9.4 jg m-2 h-1 19 - > 9.4 jig m-2 h-' Not yet reached Hochster et al (1996a)
21 dq28d
9-Amino-CPT i.v. 17-25 jig m-2 h-1 20 2.9 ± 1.6 Not yet reached Not yet reached Takimoto et al (1996)
120h/wkx3 (17gg m-2 h-')
q 4 wk
i.v., intravenous; i.p., intraperitoneal; p.o., oral; MTD, maximum-tolerated dose; DLT, dose-limiting toxicity; Cp-ss; plasma-concentration steady state; - not stated.
9NC i.m. at a dose of 4 mg kg-' twice a week (Pantazis et al,
1993a). No tumour regrowth nor toxicity occurred during
prolonged 9NC administration.
Cell cultures of non-tumorigenic breast cancer cells (MDA-
MB-134) and tumorigenic cells (MDA-MB-231) were exposed to
9NC. The non-tumorigenic cells accumulated in G2/M without
significant changes in S-fraction. Removal of 9NC from the
cultures of non-tumorigenic cells after 120 h resulted in regrowth
at a rate similar to untreated cells. In tumorigenic cells exposed to
9NC, there was a marked increase in cells containing a reduced
DNA content and going into apoptosis. Removal of9NC from the
cultures oftumorigenic cells after 120 h did not result in regrowth
after 120 h (Pantazis et al, 1993a).
Experiments with 9NC and 9AC at an i.m. dose of 4 mg kg-'
twice weekly in various human breast cancer xenografts resulted
in complete tumourregression but, regardless of9NC continuation
or discontinuation, tumorigenic MDA-MB-231 tumours regrew
after a period of 50 days ofcomplete tumour regression (Pantazis
et al, 1993b). This indicates that drug resistance occurs.
Protracted i.v. administration of 9AC to mice innoculated with
CLO human breast cancer cells was studied in various schedules.
9AC i.v. daily x 3 every 21 days at dose levels of 0.75 and
1 mg kg-1 day-' resulted in tumour regression but, ultimately, with
regrowth. This i.v. schedule had no inhibitory effect on tumour
progression, unlike the i.m. 9AC 1 mg kg-1 administration
described earlier. A 5-day period of continuous 9AC administra-
tion followed by 2 days' rest was highly effective in tumour inhi-
bition and regression even at a dose of 0.5 mg kg-' day-'. 9AC
doses of 1 mg kg-' day-1 or above were toxic for the animals.
Intragastric administration of 9NC and 9AC was studied at
different doses and schedules in mice with CLO xenografts. The
optimal 9NC and 9AC dose and schedule was 1 mg kg-' day-' for
5 days followed by 2 days' rest. The authors conclude that, for
practical reasons, oral administration is the route of choice for
9NC (Pantazis et al, 1993b).
Intramuscular administration of 9NC 4 mg kg-' twice a week
was efficacious in nude mice bearing human 2774 ovarian cancer
(Pantazis et al, 1993c). Prolonged exposure oftumorigenic (2774)
and non-tumorigenic (DUN) ovarian cancer cells in vitro to a
concentration of 1 ng ml-' of 9NC resulted in accumulation of
non-tumorigenic cells in G/M and accumulation of tumorigenic
cells containing reduced DNA content and going into apoptosis
(Giovanella et al, 1994).
In a human melanoma xenograft model intramuscular adminis-
tration gave the best anti-tumour effects of9NC, 9AC and CPT. A
dose schedule of2 mg kg-' day-1 x2 with 1 day rest compared with
1 mg kg-' day-' x5 with 2 days' rest was more effacicious for CPT
and equally effective for 9NC (Pantazis et al, 1994b).
Intragastric application of 9AC on a 5-day/week schedule for
3-6 weeks induced complete remission in subcutaneous human
xenografts of malignant melanoma and non-small-cell lung carci-
noma, and its efficacy was better than that of 20-S-camptothecin
(Rubin et al, 1994).
Two observations can be made on these preclinical studies:
lower 9NC or 9AC concentrations applied for long periods of
treatment are more effective in inducing apoptosis than higher
concentrations for short periods. When 9NC initiates the process
of apoptosis in tumorigenic cells, this is not reversible, even after
removal of the drug. Non-tumorigenic cells are reversibly inhib-
ited as long as drug exposure continues.
Route of administration and dose scheduling of 9NC and 9AC
seem to be crucial foroptimal anti-tumourresponses. Prolonged or
intermittent administration of a lower dose of these drugs is most
efficacious.
Clinical studies with prolonged or continuous exposure
72-h infusion
Phase I studies of 9-amino-camptothecin in adult patients with
solid tumours have been performed initially with continuous i.v.
infusion over 72 h (Table 1). Leucopenia appeared to be the
dose-limiting toxicity, together with modest thrombocytopenia.
Nausea and vomiting, alopecia, stomatitis and diarrhoea were less
frequently reported (Rubin et al, 1994; Takimoto et al, 1994;
Dahut et al, 1996). Steady-state plasma concentrations increased
linearly with the dose and ranged from 0.9 to 10.6 nm and
correlated well with percentage decrease of granulocyte count
(Takimoto et al, 1994). In a similar phase I study in children, side-
effects were similar, but the MTD in children exceeded that in
adults (Langevin et al, 1996).
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Prolonged exposure
Phase I studies with longer infusion durations of 9-AC in adults
are ongoing. A continuous i.v. infusion for 120 h weekly for 3 out
of every 4 weeks is feasible, with DLT not yet being reached at
the dose level of 20 ,ug m-2 h- . The resulting dose intensity is
already higher than the dose intensity ofthe recommended phase
II dose of 35 ug m-2 h-' over 72 h when given every 2 weeks
(Takimoto et al, 1996).
The same holds for continuous infusion of9AC for 21 consecu-
tive days every 28 days (Hochster et al, 1996a). The latter phase I
studies suggest that with prolonged infusion a higher dose inten-
sity of9AC can be achieved. A phase I study with oral 9-NC given
for 5 consecutive days every week revealed haematological toxi-
city as being dose limiting. Non-haematological toxicity was
substantial with nausea/vomiting, diarrhoea and haemorrhagic
cystitis. An interesting level of anti-tumour activity was reported
(Verschraegen et al, 1996).
Further studies on prolonged dosing of oral 9NC and i.v. 9AC
are presently on-going.
In summary, dose intensities are higher for 9AC when adminis-
tered with longer infusion duration. Oral administration of9NC for
5 consecutive days gives substantial non-haematological toxicity.
TOPOTECAN
Topotecan (TPT, 9-dimethylaminomethyl-10-hydroxycampto-
thecin) is a water-soluble potent camptothecin analogue with
activity against various tumour types in in vitro and in vivo studies.
Preclinical studies
In vitro studies
In vitro effects oftopotecan against cells frombiopsy specimens of
colorectal, breast, lung, ovarian, renal, gastric cancer and cancers
ofunknown primary origin were studied with 1-h and with contin-
uous exposure in a human tumourclonogenic assay. With 1-h TPT
exposure in vitro, responses were seen in 10% and 25% of
assessable tumour specimens at TPT concentrations of 1.0 and
10.0 ,ug ml-' respectively. Response rates were 34% and 76% at
concentrations of 0.1 and 1.0 ,ug ml-1 TPT with continuous expo-
sure (Burris et al, 1992), suggesting that TPT was more active
with long-term incubation. Continuous exposure of TPT in vitro
showed an initial decrease of the active lactone form of TPT,
followed by a stable ratio up to 72 h, which corresponded to 19%
of the initial value. The fraction of the lactone form during 1-h
exposure is not known, but nevertheless it is very likely that the
concentration-time product (dose intensity) is greater for contin-
uous exposure than for 1-h exposure (Burris et al, 1992). This
implies that the time period of exposure to topotecan is an even
greater determinant ofcytotoxicity than anticipated.
In vivo studies
Different TPT schedules were studied in female CBA/CaJ
immune-deprived mice engrafted with seven colon carcinoma cell
lines, six juvenile rhabdomyosarcomas and three osteosarcoma
cell lines (Houghton et al, 1991). Initially, TPT was administered
intraperitoneally (i.p.) using a schedule offourdoses ofTPT every
4 days (q4d x 4 schedule). The maximum-tolerated dose (MTD)
with this schedule was 12.5 mg kg-' per administration, and TPT
caused significant regression in four of five rhabdomyosarcoma
xenografts. Subsequently, the effect of TPT was studied as a daily
x5 dose given for 3 consecutive weeks by oral gavage (2 mg kg-1
per administration) or daily x 5 for 3 weeks intraperitoneally.
Intraperitoneal administration was at least as efficacious as oral
dosing but more toxic (Houghton et al, 1991). Intraperitoneal TPT
2 mg kg-1 per dose was lethal in more than 15% of the mice, the
MTD with intraperitoneal administration was 1.5-1.75 mg kg-'
per dose. The effect of prolonged topotecan administration was
studied in two moderately responsive xenografts, Rh 12 rhabdo-
myosarcoma and VRCs colon adenocarcinoma. Mice bearing Rh
12 rhabdomyosarcoma xenografts were treated with TPT 2.0 or
1.75 mg kg-1 per dose day-1 x 5 for three courses or a lower dose
(1.25 mg kg-1 per dose) for up to 20 courses. The prolonged
low-dose regimen resulted in complete remission of all tumours
without regrowth. The same effect was seen at an even lower dose
level of 1.0 mg kg-1 per dose, also without significant toxicity.
Mice with VCR5 colon adenocarcinoma showed significant
tumour reduction with prolonged oral administration of TPT at a
dose of 1.0 mg kg-' per dose x 5 for 20 cycles. However, regrowth
occurred after 16 weeks.
Additional studies with prolonged exposure schedules in mice
bearing xenografts of colon adenocarcinoma, rhabdomyosarcoma
and brain tumours showed less toxicity and better anti-tumour
activity than dose-intensive short-exposure schedules (Houghton
et al, 1995). These in vivo studies show that oral administration is
as efficacious as parental application, although the AUC is lower
with oral administration.
Furthermore, prolonged intraperitoneal and oral (p.o.) TPT
administration resulted in responses of xenografts not respon-
sive to a short-term parental intermittent high-dose schedule
(Houghton et al, 1991, 1995).
From these preclinical data, prolonged exposure to topotecan
seems a treatment schedule with a potentially higher benefit with
regard to anti-tumour activity.
Clinical studies with prolonged or continuous exposure
Dailyx5 i.v. administration
Phase I studies with single i.v. bolus daily for 5 days repeated
every 3-4 weeks show a maximum-tolerated dose of 1.5-
2.5 mg m-2 day-'. The dose-limiting toxicity was myelosuppres-
sion, in particular neutropenia (Rowinsky et al, 1992; Saltz et al,
1992; Verweij et al, 1993).
Non-haematological toxicities were usually mild and reversible
and consisted of nausea, vomiting, fatigue, alopecia and some-
times diarrhoea.
Phase II studies with this daily x5 TPT regimen every 21 days
showed promising response rates in patients with small-cell lung
cancer (10-39%) and in pretreated patients with ovarian cancer
with response rates ranging from 9.5% to 25% (Kudelka et al,
1993; Schiller et al, 1994; Armstrong et al, 1995; Wanders et al,
1995; Carmichael et al, 1996; Malmstrom et al, 1996; Creemers et
al 1997). Other solid tumours, such as melanoma, colon carcinoma,
head and neck cancer, renal cell carcinoma, cervix and prostate
carcinoma, appear to be much less sensitive to this regimen (Ilson
et al, 1993; Roethke et al, 1993; Lynch et al, 1994; Robert et al,
1994; Sugarman et al, 1994; Kraut et al, 1995; Puc et al, 1995;
Noda et al, 1996; Perez Soter et al, 1996; Smith et al, 1996). In
these phase II studies, CTC grade III-IV neutropenia (32-81%)
was reported as being the major toxicity. Thrombocytopenia CTC
grade III-IV is infrequent. Anaemia greater than CTC grade II was
reported in 27-60%.
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Table 2 Topoisomerase inhibitors - continuous/prolonged administration in solid tumours (topotecan)
Drug Dose (mg m-2) Number of patients Cp-ss MTD DLT Reference
schedule
Topotecan i.v. 2.5-5.0 15 - 4 mg M-2 24 h-1a Neutropenia Recondo (1991)
24 h q 3 wk Thrombopenia
5 mg m-2 24 h-lb
Topotecan i.v. 2.5-5.0 10 4-10 ng ml-1 - Neutropenia Reid (1992)
24 h q 3 wk
Topotecan i.v. 2.5-10.5 22 20 ng ml-' 8.4 mg m-2 24 h-1 Neutropenia ten Bokkel
24 h q 3 wk Huinink (1992)
Topotecan i.p. 3-4 12 - 4 mg m-2 24 h-1 Neutropenia Plaxet et al (1993)
24 h q 4 wk
Topotecan i.v. -/72 h q 1 wk 12 - 2 mg m-2 72 h-' Neutropenia Sabiers et al (1993)
-/72 h q 2 wk 7 - 2.6 mg m-2 72 h-1 Neutropenia
72 h
Topotecan i.v. + G-CSF 10-15 13 - 4 mg m-2a Neutropenia Abbruzzese (1993)
24 h q 3 wk 10 mg m-2b (+G-CSF:
Thrombopenia)
Topotecan i.v. 2.0-7.5 29 18.2 ± 3.7 nm 7.5 mg m-2 Neutropenia Blaney (1993)
24 h q 3 wk Thrombopenia
Topotecan i.v. 1.0-2.0 32 4.7-11.4 nM 1.75 mg m-2 24 h-' Neutropenia Haas (1994)
24 h q 1 wk
Topotecan i.v. 0.75-1.9 day-' 27 3.1 ± 1.4 ng ml-' 1.3 mg m-2 Neutroperia Pratt (1994)
1.0 mg m-2 d-'
72 h q 3 wk
Topotecan i.v. 0.17-0.68 day-' 14 5.5 ng ml-' 0.68 mg M-2 day-' Thrombopenia Burris (1994)
120 h q 3 wk
0.68-1.6 day-' 32 2.0 ng ml-' 1.6mg m-2 day-' Neutropenia
72 h q 3 wk
Topotecan i.v. 0.2-0.7 44 - 0.53 mg m-2 day-' Thrombopenia + Hochster et al (1994)
21 d q 28 d Neutropenia
Topotecan i.v. 0.6 day-' 21 d 9 - - Neutropenia Khater (1995)
Thrombopenia
Topotecan i.v. 0.4 day-' 16 - - - Hochster et al (1996)
21 d q 28 d (Phase II)
Topotecan i.v. 0.8-1.1 day-' 12 - 0.8mg m-2 day-' Thrombopenia Bowman et al (1996)
21 d q 28 d Pediatric
aChemotherapy pretreated. bNon-pretreated. i.v., intravenous; i.p., intraperitoneal, p.o. oral; MTD, maximum-tolerated dose; DLT, dose-limiting toxicity; CP-ss,
plasma-concentration steady state; - not stated.
Prolonged exposure
Continuous infusion of topotecan has been studied in various
schedules: a 24 h infusion weekly and every 3 weeks; a 72 h
infusion administered weekly, every 14 days and every 21 days;
a 120-h infusion every 3-4 weeks; and a 21-day continuous
infusion administered every 28 days (Table 2).
In one study, TPT was administered intraperitoneally for 24 h
every 4 weeks (Plaxe et al, 1993). Studies with continuous infu-
sion of topotecan of 72 h or more show mild non-haematological
toxicities (nausea, vomiting, alopecia). Dose-limiting toxicity is
always leucocytopenia, more often with associated thrombo-
cytopenia than with the daily x 5 i.v. bolus. Anaemia requiring
blood transfusions and thrombocytopenia with platelet transfu-
sions areparticular problems related to these schedules. In phase II
studies in paediatric patients and adults with acute leukaemia,
continuous infusion ofTPT for 120 h resulted in severe mucositis
as DLT (Kantarjian et al, 1993; Furman et al, 1996).
In a phase I study with continuous intravenous topotecan
administration for 21 days every 28 days in 44 patients with solid
tumours, the MTD was 0.53 mg m-2 day-', with myelosuppression
as DLT (Hochster et al, 1994). The steady-state lactone TPT
concentration was low, approximately 4 ng ml-'. No consistent
relationship was found between drug level and haematological
toxicity. Partial tumor responses were noted in two patients with
ovarian cancer, one patient with breast cancer, one patient with
renal cell cancer and one patient with non-small-cell lung cancer
(NSCLC) (Hochster et al, 1994). Blood transfusions and platelet
transfusions were necessary in 45% and 11% of patients respec-
tively. The authors concluded that a 21-day infusion of TPT is
generally well tolerated with minimal non-haematological toxi-
city. In a phase II study with this regimen in patients with progres-
sive ovarian cancer after platinum-containing chemotherapy,
response rate was 37% and neutropenia was the major toxicity
(31%). Blood transfusions needed to be given to 50% of patients
(Hochster et al, 1996b). Further phase II studies with the 21-day
continuous infusion ofTPT are ongoing.
The bioavailability of oral TPT varies from 32% to 44% with
relatively limited intrapatient variation (Kuhn et al, 1995;
Schellens et al, 1996). Oral TPT was studied in paediatric patients
with solid tumours in a phase I study with two different dose
schedules. In one dose schedule, TPT was administered orally
every day for 21 days out ofevery 28 days; in the second schedule,
oral TPT was given 5 days on and 2 days off for 15 total doses.
In the 21-day schedule oral bioavailability was 46 ± 22% at
0.8 mg m-2 and 34 ± 14% at dose level 1.1 mg m-2. DLT of both
schedules is thrombocytopenia, and myelosuppression is well
correlated with systemic exposure to oral TPT (Bowman et al,
1996). Thus, in vitro studies show that time period of exposure to
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Table 3 Topoisomerase inhibitors - continuous/prolonged administration in solid tumours (CPT-11)
Drug Dose (mg m2) Number of patients Cp-ss MTD DLT Reference Year
Schedule
CPT-11 i.v. 125-225 20 - >200mg m-2 Not yet Rothenberg (1996)
every other reached
wk
CPT-11 i.v. bolus. 33-115 day-' 46 2034 ng ml-' 115mg m-2 Neutropenia + Catimel et al (1995)
3d q 3 wk diarrhoea
CPT-11 i.v. 5-40 day' 36 6.8-10.5 ng ml-' 40 mg m-2 day' Neutropenia Ohe et al (1992)
120 h q 3 wk (SN 38) diarrhoea
i.v., Intravenous; i.p., intraperitoneal; p.o, oral; MTD, maximum-tolerated dose; DLT, dose-limiting toxicity; Cp-ss, plasma-concentration steady state; -, notstated.
topotecan is an important determinant of cytotoxicity. In vivo
studies with human xenografts with prolonged administration of
topotecan show better anti-tumour activity. In patients with solid
tumours, continuous infusion ofTPT is well tolerated, and tumour
responses are being reported. Phase I studies with an oral formula-
tion ofTPT in adult patients with solid tumours are ongoing.
IRINOTECAN (CPT-1 1)
CPT- 1I (7-ethyl-10 [4-(piperidino)-1-piperidino]carboxyloxy-camp-
tothecin) is a water-soluble analogue of camptothecin. CPT-11 has
little inherent anti-tumour activity in vitro, but it is converted to SN-
38, a metabolite that is 1000-fold more potent than the parent
compound in vitro (Kawato etal, 1991; Kanzawa et al, 1993).
Preclinical studies
In vivo studies
CPT-11 has been studied in human tumour xenografts with
chemorefractory colon-carcinoma, chemoresponsive rhabdo-
myosarcoma and sublines of rhabdomyosarcoma with in vivo
resistance to vincristine, melphalan and topotecan, as well as with
three paediatric brain tumours (Houghton et al, 1993, 1995).
As a single i.v. administration at the maximum-tolerated dose
(50 mg kg-'), CPT-11 had no inhibitory effect on any colon carci-
noma xenograft; however, when administered for one cycle i.v. at
a dose of 10-40 mg kg-' per dose daily x5 for 2 consecutive
weeks, it demonstrated significant activity against five of
eight colon carcinoma models. Rhabdomyosarcomas and two
xenografts (Rh 18 rhabdomyosarcoma and VRCs colon adenocar-
cinoma), resistant in vivo to topotecan, were also highly respon-
sive to this schedule (Houghton et al, 1993). To determine whether
prolonged periods of treatment were more effective CPT-11 was
administered as before as a daily x5 schedule for 2 weeks, but the
cycles were repeated every 21 days for a total ofthree cycles. The
MTD was 10 mg kg-' day-'. Complete regression of all VRC5
colon tumours was achieved at 5-10 mg kg-' per dose. CPT-11,
given as a protracted schedule at 5 mg kg-' day-', showed greater
activity than a shorter intense therapy at40 mg kg-' per dose.
A single cycle ofCPT-11 was only modestly active at a dose of
40 mg kg-' in 4 of 25 Rh 12 rhabdomyosarcoma xenografts
whereas three cycles of therapy at 10 mg kg-' day-', daily x 5,
resulted in complete regression in 12 of 13 tumours. Similar
results were obtained in colon carcinoma and human brain tumour
xenografts (Houghton et al, 1993).
Thus, protracted therapy with low-dose CPT-11 has increased
therapeutic efficacy compared with more toxic short-term schedules.
Clinical studies with prolonged or continuous
administration
In a phase I study with CPT-11 given as a 5-day continuous infu-
sion every 3 weeks, the dose was escalated from 5 to 40 mg m-2
day-' (Ohe et al, 1992) (Table 3). Dose-limiting toxicity consisted
of CTC grade III-IV diarrhoea. Toxic effects greater than CTC
grade II included diarrhoea (69%), nausea and vomiting (58%),
leucopenia (25%), anaemia (25%), thrombocytopenia (6%) and
hepatic dysfunction (14%). Diarrhoea was dose dependent, in
contrast to the white blood cell nadir, which was not dose depen-
dent (Ohe et al, 1992). In another phase I study, CPT-11 was
administered intravenously over 30 min for 3 consecutive days
every 3 weeks. Both leucopenia and diarrhoea were dose limiting
at a dose of 115 mg m-2 day-1 (Catimel et al, 1995).
In limited studies with low-dose schedules ofCPT- 1I oncedaily
x 3, once daily x 5 andtwice daily x 7, anti-tumourresponses were
reported in patients with leukaemia and lymphomas (Ohno et al,
1990; Tsuda et al, 1992).
From small studies in ovarian and cervical cancer, it was
suggested that there were no significant differences between
schedules conceming efficacy, but clearly these data need further
confirmation (Takeuchi et al, 1991a and b). Response rates in
patients with NSCLC treated with CPT- 1I at a dose of200 mg m-2
every 3-4 weeks or 100 mg m-2 weekly do not seem to differ
(Nakai et al, 1991; Negoro et al, 1991). In patients with solid
tumours, the dose schedule apparently does not seem to be crucial
in efficacy ofthe drug. However, CPT-11 may have more efficacy
when administered atlowerdoses foralongertime topatients with
malignant lymphoma.
An oral formulation of CPT-11 has been tested on a daily x 5
schedule every 3 weeks with diarrhoea and neutropenia as dose-
limiting toxicities (Drengler et al, 1996).
G114721 1
G1147211, (7-(4-methyl piperazinomethylene)10,11-ethylene-
dioxy-20-(S)-camptothecin) is a water-soluble analogue of
camptothecin. The water-solubilizing groups were introduced on
position 7 in the B ring.
Preclinical studies
GI14721 1 appeared to have anti-tumouractivity in vitro as well as
in vivo (Emerson et al, 1995). In these studies, the dose schedule
of twice a week administration for 5 weeks did not appear
optimal. Recent data demonstrate that G1147211 is more active
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Table 4 Topoisomerase inhibitors - continuous/prolonged administration in solid tumours (Gil147211)
Drug Dose (mg m-2) Number of of patients Cp-ss MTD DLT Reference
Schedule
G1147211 i.v. 0.3-0.5 day-' 38 0.1-0.35 ng ml-' 0.5 mg m-2 d-1 x 21 Neutropenia Khater et al (1996)
7-21 d q 28 d Thrombopenia
G1147211 i.v. 72 h q 28 d? 36 - 1.5 mg m-2 d-1a Myelosuppression O'Dwyer et al (1995)
2.0 mg m-2 d-lb
aChemotherapy pretreated. bNon-pretreated. i.v., Intravenous; i.p., intraperitoneal, p.o, oral; MTD, maximum-tolerated dose; DLT, dose-limiting toxicity;
Cp-ss, plasma-concentration steady state; -, not stated.
when administered at higher doses using an every 4 days schedule
for a total of three doses (Emerson et al, 1994). Again, dose
scheduling seems to be important for an optimal anti-tumour
effect.
Clinical studies with prolonged or continuous
administration
Dailyx5 i.v. administration
Three phase I studies with intravenous G114721 have been
performed, two studies with a 30-min GI147211 infusion once
daily for 5 consecutive days every 3 weeks, a third study with
GI147211 given as a 72-h continuous infusion (Eckardt et al,
1995; O'Dwyer et al, 1995; Gerrits et al, 1996). In all studies,
AUC increased with dose in a linear fashion, and dose-limiting
toxicity consisted of leucocytopenia as well as thrombocytopenia.
Non-haematological toxicity was mild and there was no diarrhoea
or haemorrhagic cystitis. Preliminary results of phase II studies
show anti-tumour activity in ovarian cancer and small-cell lung
cancer (Wanders et al, 1996).
Prolonged exposure
A phase I study with continuous infusion of G1147211 has been
performed with doses ranging from 0.3 to 0.5 mg m-2 day-' for 7,
14 and 21 days. DLT reached at 0.5 mg m-2 day-' consisted of
neutropenia and thrombocytopenia. Non-haematological toxicities
CTC grade 2 II consisted of nausea, vomiting, dyspepsia, fatigue
and diarrhoea. Pharmacokinetics of G1147211 showed mean
steady-state concentrations ranging from 0.1 to 0.35 ng ml-'. The
total body clearance was similar to the clearance with shorter
infusions (Khater et al, 1996) (Table 4).
DISCUSSION AND CONCLUSION
Topoisomerase I inhibitors are a class of drugs with a broad anti-
tumour activity, even against previously chemotherapy-resistant
tumours. The issues concerning drugs scheduling are many, and
one of the conclusions from this review could be that there is no
true consistency in the use of schedules and models in preclinical
studies. It would be worthwhile to try to achieve this consistency
in the development of drugs such as these. Clearly, many of the
relevant questions on scheduling can already be answered in in
vitro studies, such as the ones that have been performed with
topotecan. With appropriate in vitro studies, one could easily
mimic potential clinical application schedules. Following in vitro
studies, in vivo studies could be performed taking the data from
the in vitro studies into account. Obviously, long-term infusional
application in animal models is difficult to achieve but, on the
otherhand, many ofthe performed in vivo studies, because oftheir
diversity, do not result in conclusive evidence. With a consistent
approach in preclinical studies, one could also avoid the need to
perform too many clinical studies on scheduling. We also recom-
mend performing the clinical phase I and II studies with inclu-
sion of pharmacokinetic/pharmacodynamic (PK/PD) relationship
studies. A good example ofthis can be found in a yet unpublished
study relating levels of topoisomerase I inhibitors to parameters
such as decreased cleavable complex formation. Making use ofthe
appropriate combinations of clinical studies with PK/PD studies,
the number of studies necessary could easily be reduced. Also,
such studies would answer the question of whether thresholds
exist for the effect of topoisomerase I inhibitors in conjunction
with exposure duration. The preliminary results from the above
reviewed phase I and phase II studies indicate that prolonged
administration with topoisomerase I inhibitors is feasible in
patients with cancer. However, unfortunately, the optimal dose and
schedule of the various agents available remain to be elucidated.
Although preliminary results are encouraging and warrant further
clinical exploration, the concept should still be considered as being
investigational.
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